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No surgical innovation without evaluation: Evolution and further development of the IDEAL 
Framework and Recommendations.  
This paper updates the IDEAL Framework and Recommendations following review at 
international expert meetings held during IDEAL Conferences in Oxford, UK in 2016 and New 
York, USA in 2017. 
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Running Head: IDEAL Framework & Recommendations Update 
Mini-Abstract: The IDEAL Recommendations provide a logical stepwise pathway for 
evaluating surgical operations, therapeutic devices and other complex interventions through 
five definable life-cycle stages (Idea, Development, Exploration, Assessment and Long term 
study).  This new paradigm for research has matured since its launch in 2009, and this 
comprehensive update clarifies its use. 
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Structured Abstract: 
Objective: To update, clarify and extend IDEAL concepts and recommendations. 
Background: New surgical procedures, devices and other complex interventions need robust 
evaluation for safety, efficacy and effectiveness.  Unlike new medicines, there is no 
internationally agreed evaluation pathway for generating and analysing data throughout the 
life cycle of surgical innovations.  The IDEAL Framework and Recommendations were 
designed to provide this pathway and they have been used increasingly since their 
introduction in 2009.  Based on a Delphi survey, expert workshop and major discussions 
during IDEAL conferences held in Oxford (2016) and New York (2017), this article updates and 
extends the IDEAL Recommendations, identifies areas for future research, and discusses the 
ethical problems faced by investigators at each IDEAL stage. 
Methods: The IDEAL Framework describes five stages of evolution for new surgical 
therapeutic interventions – Idea, Development, Exploration, Assessment and Long Term 
Study.  This comprehensive update proposes several modifications. First, a “Pre-IDEAL” stage 
describing pre-clinical studies has been added.  Second we discuss potential adaptations to 
expand the scope of IDEAL (originally designed for surgical procedures) to accommodate 
therapeutic devices, through an IDEAL-D variant.  Third, we explicitly recognise the value of 
comprehensive data collection through registries at all stages in the Framework and fourth, 
we examine the ethical issues that arise at each stage of IDEAL and underpin the 
recommendations. The Recommendations for each stage are reviewed, clarified and 
additional detail added. 
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Conclusions: The intention of this article is to widen the practical use of IDEAL by clarifying 
the rationale for and practical details of the Recommendations. Additional research based on 
the experience of implementing these Recommendations is needed to further improve them. 
INTRODUCTION 
Surgery is a complex intervention with properties which make it more difficult to evaluate 
rigorously than drug treatments.  Evaluation methods that fail to address this complexity have 
led to much controversy and wasted effort through poor study design, inadequate reporting 
and failure to reach agreement on standards for high quality trials.   The resulting adverse 
consequences have included widespread adoption of new techniques or devices which later 
proved to be harmful and of refusal by healthcare funders to reimburse for innovations with 
an inadequate evidence base, as well as large scale failures of surgical research to compete 
successfully for public funding.  
The IDEAL Framework and Recommendations represent a new paradigm for the evaluation 
of surgical operations, invasive medical devices and other complex therapeutic interventions.  
IDEAL began with a series of meetings at Balliol College, Oxford during 2007-9 to discuss the 
specific challenges of evaluating surgical innovation, recognising, analysing and proposing 
solutions for the challenges which arise as new procedures move from proof of concept 
towards a randomised controlled trial. These discussions resulted in the publication of a five-
stage Framework describing the natural stages of surgical innovation (Idea, Development, 
Exploration, Assessment and Long Term Study), together with recommendations for a 
rigorous stepwise surgical research pathway, and suggestions for appropriate study 
methodology for the questions which characterise each stage. (1, 2, 3) This was subsequently 
followed up by publications offering methodological guidance. (4, 5, 6, 7)  
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Each stage is defined by a key research question: 
• IDEA - STAGE 1: What is the new treatment concept and why is it needed?  
• DEVELOPMENT - STAGE 2a: Has the new intervention reached a state of stability 
sufficient to allow replication by others? 
• EXPLORATION - STAGE 2b: Have the questions that might compromise the chance of 
conducting a successful RCT been addressed? 
• ASSESSMENT - STAGE 3: How does the new intervention compare with current 
practice? 
• LONG-TERM STUDY- STAGE 4: Are there any long-term or rare adverse effects or 
changes in indications or delivery quality over time? 
Various users and funders of research have acknowledged the utility of IDEAL. (Table 1) 
Surgical researchers are also increasingly citing and using the study designs and reporting 
formats recommended by IDEAL (552 papers cited key IDEAL papers [Web of Science 
searched 19 October 2017]). Despite these signs of interest, international use of IDEAL 
remains limited. It is clear that researchers need more detailed guidance about how to 
implement the recommendations (8, 9, 10) which were initially outlined in a generalised way.  
We revised and updated the Framework and Recommendations using a three-step modified 
Delphi process comprising a two-round online questionnaire survey between December 2015 
– April 2016 followed by an expert consensus meeting at the IDEAL Conference at St 
Catherine’s College, Oxford on 8th April 2016 (Appendix 1- link 1).  The first round required 
participants to address 22 questions aimed at clarifying the IDEAL Recommendations, and the 
second round was focused on 11 areas where consensus was not clear in round 1, with 
remaining areas of controversy dealt with at the Oxford meeting.  The international group of 
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experts comprised 56 participants (47 attended the final meeting) including surgeons, 
methodologists, clinical trialists, ethicists, journal editors, HTA professionals, purchasers of 
healthcare and device industry representatives.  Further details of the process and findings 
are provided (Appendix 2). 
SCOPE 
Discussions about updating IDEAL covered four main new areas. First, the need for a pre-
IDEAL, pre-clinical Stage.  Second, the application of IDEAL to other complex health 
interventions. Third, a reconsideration of the place of registries in the IDEAL pathway, and 
finally an explicit examination of the ethical issues that arise at each stage of IDEAL and 
underpin the recommendations 
Publications reporting pre-clinical studies prior to ‘first in human’ studies as “IDEAL Stage 0” 
have already appeared (11). However, due to the challenge of drafting recommendations for 
conduct and reporting of such a potentially broad and varied set of different study types, we 
recommend the use of the term ‘Pre-IDEAL’ for these studies rather than adding a formal 
“Stage 0” to the Framework.   
IDEAL’s potential for application to therapeutic medical device evaluation was quickly 
recognised (Appendix 1-link 2), and the necessary modifications have already been 
summarized in a description of an IDEAL-D (Devices) variant (12) supported by an 
international Delphi process (13). Other specific variants have also been proposed, such as 
the R-IDEAL tool from the MRI-Linear Accelerator Consortium (14) and IDEAL-Physio (15). 
However, the consensus group agreed not to broaden the scope of the original IDEAL 
Framework, but to welcome and monitor the work of groups investigating potential wider 
uses.   
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With the help of academic ethicists, the scope of the IDEAL Framework and 
Recommendations has been expanded to include explicit ethical guidance at each stage. 
Ethical issues arising in each of the IDEAL stages are examined in detail in an accompanying 
paper. (16) 
UPDATE OF IDEAL: STAGE BY STAGE  
The 2009 Framework comprised five stages: Idea (1), Development (2a), Exploration (2b), 
Assessment (3) and Long-term study (4). (3) The main purpose of each stage is summarised 
above. 
We updated the original Framework to improve its usability and transparency. This update 
includes description of each IDEAL stage using the PICO framework (patients/operators, 
interventions, comparators, outcomes), identifying appropriate reporting guidelines and 
identifying when to progress to the next stage. We also underline the key research question 
for each IDEAL stage and highlight areas for future research. The revised and original versions 
are shown side by side to clarify the changes made in this update. (Table 2) 
Pre-IDEAL studies  
Purpose and description  
Pre-IDEAL research is essential prior to first in human trials of an innovation.  
Patients and operators:  Although patients do not receive treatments in Pre-IDEAL studies, 
consultation is desirable to evaluate the societal need and perceived value of the proposed 
intervention. (17) Where the investigators are engineers or scientists with no clinical 
background, clinicians should also be consulted.  
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Intervention and comparator: Pre-clinical studies usually do not involve a comparator. 
However, testing (e.g. surface wear, battery drain), simulation or modelling studies may allow 
comparison with the current standard. 
Outcomes: Depending on the type of pre-clinical study, the aims and methods may vary 
widely. Typically, key studies focus on demonstrating that the intervention brings about the 
intended physical changes. Following this, studies to estimate reliability and safety, 
qualitative studies with stakeholders to determine potential demand and acceptability, and 
modelling studies to predict overall impact on health care costs/efficiency may be desirable. 
This is especially relevant for new devices for purpose of coverage and reimbursement.  
Appropriate study designs 
Pre-clinical studies include material testing, simulator, cadaver, animal, modelling and cost-
effectiveness studies. (18, 19, 20)  
Controlled experiments will often be appropriate and feasible for laboratory or bench 
studies.  Because of the wide range of study objectives and methods, comprehensive 
recommendations about study design are impractical.  We therefore recommend following 
the best available authoritative guidance on particular study types. (Appendix 1- link 3)  
Recommended reporting guidelines for protocols and full reports 
Explicit reporting of Pre-IDEAL findings is both practically and ethically necessary to support 
optimal development of Stage 1 studies.  However protection of professional or commercial 
advantage may inhibit full reporting. Transparency around study design, subjects and 
outcomes is essential, but recommendations for reporting of sensitive details of mechanism 
or technique at this stage may prove impractical. We recommend using the numerous high 
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quality, subject-specific guidelines that exist for reporting different kinds of preclinical studies 
and protocols which can be found on the EQUATOR and Meridian Network databases (Appendix 
1- link 4), or at the National Institutes of Health (Appendix 1- link 5) 
Ethical aspects  
Animal studies should abide by recognised ethical guidelines, including the imperative to 
reduce, refine, and replace animal use whenever possible (Appendix 1- link 6). Animal models 
must be valid and the results applicable to humans. Pre-IDEAL simulation and bench testing 
can raise ethical considerations of justice where assumptions built into testing (e.g. about 
typical body shapes) may limit the applicability of the results, or expose subgroups to greater 
risk of harm (16).  
Identifying stage endpoints 
In principle, the pre-IDEAL stage should be complete before the first in human procedure is 
done.   Any feasible studies which can be expected to identify avoidable and/or predictable 
risks of failure or harm to the first patient should be performed. 
“Idea” Stage 1 - ‘First in human’ use 
Purpose and description 
IDEAL Stage 1 describes the first use of a new procedure or device in a patient, either as part 
of a planned approach or in an unplanned emergency situation. (21)  Where planned, the 
patient or patients are usually highly selected.  
Patients and operators: Patient selection criteria should be explained in detail: if any 
proposed patients refuse the procedure, or are excluded, this should be explained with 
reasons.  The operators are usually an individual or small team in a single centre.  
8 
 
 
Intervention:  A full technical description of the new procedure or technology, in sufficient 
detail to allow an equivalently skilled operator to reproduce it, should be provided. There is 
normally no explicit comparator. 
Outcomes:  Commonly include technical success, safety and short-term physiological and 
clinical measures.  Transparency demands that all adverse events must be fully disclosed. 
Whenever feasible, in all stages of IDEAL, outcomes should be described using widely 
accepted standardised definitions and terms, preferably selected from a core outcomes set 
(Appendix 1- link 7). 
Appropriate study designs 
Stage 1 involves a single case or a few cases. If enough suitable patients are available 
progression may occur within a short time. It is recommended that reports explain the need 
for the new treatment concept and why it might be better than currently available treatment. 
Video recording and sharing is highly recommended and can be part of on-line publication. 
Recommended reporting guidelines for protocols and full reports 
We recommend Stage 1 studies be reported as a single case report. The SCARE Guidelines 
provide a useful standard reporting structure. (22) Menon et al (11) demonstrate a well 
reported IDEAL model of surgical innovation in the development of robotic kidney 
transplantation (RKT) with regional hypothermia.  
 
Ethical aspects   
Significant ethical issues arising in Stage 1 include: minimising patient harm; ensuring 
adequately informed patient consent; optimising communication about the innovation in the 
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surgical team; identifying and managing conflicts of interest; and obligatory full and accurate 
reporting of outcomes to prevent avoidable harms to future patients. Reflection is important 
to confirm the potential for the new innovation to solve a real clinical problem. Planned 
innovations should be conducted in compliance with local hospital and research ethics 
frameworks such as IRBs. Local organisations should be responsible for ensuring that review 
supports rather than discourages innovation (16).  
Identifying stage endpoints  
Once Stage 1 is completed, deciding whether to progress to Stage 2a depends on proof of 
concept, technical achievement, apparent safety and potential efficacy.   
Areas for future work & research   
The IDEAL Collaboration strongly recommends registration of all first-in-human procedures. 
There is an ethical obligation on investigators to make their research available to others 
contemplating similar interventions. Registration of unsuccessful interventions is critical to 
prevent repetition of harmful errors. However, investigators may be discouraged if 
transparency exposes them to legal and other challenges. Therefore regulatory and 
governance frameworks need to evolve to accommodate these tensions.  Public interest 
protection rules similar to those shielding accident investigations in the transport industries 
could achieve this. The recently enacted UK “Access to Medical Treatments (Innovations) Bill” 
allows the creation of a “medical innovations register” which, with appropriate protection 
could represent an IDEAL Stage 1 register (Appendix 1- link 8) 
Incentives may be necessary to ensure that innovations with adverse outcomes are 
registered. Potential mechanisms to achieve this include making reporting a professional or 
legal obligation or requiring registration as a pre-requisite to publishing first-in-human case 
reports.  
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“Development” (Stage 2a) – Towards stabilisation of the technique 
Purpose and description 
In IDEAL Stage 2a, procedures are typically undergoing iterative modification towards a final, 
stable version.  
Patients and operators: Usually only a few tens of patients and a few operators are involved, 
within a single institution for technique-based innovations.  For new devices the number of 
operators and centres may be larger.  
Intervention: A technical description of the initial version of the intervention is needed and 
an account of when, why and how modifications to either technique or selection criteria were 
made (23). No comparator is involved this stage. For example, Diez del Val et al (23) report 
the development of robotically assisted oesophagectomy by a two-surgeon team from the 
first robotic case onwards, presenting the cases sequentially and showing key outcomes 
(blood loss, robotic operating time, lymph node yield, length of stay and complications) for 
each patient. The reasons for rejecting cases for robotic surgery are explained, and all changes 
to technique or indication are highlighted, showing when they occurred and explaining why 
they were instituted. 
Outcomes: Relevant outcomes include short-term clinical, technical and safety outcomes.  
Appropriate study designs 
Normally a small single centre prospective cohort. A typology which deconstructs 
interventions into their component parts may help with precise definition of procedures, and 
clarify description of which parts of the procedure change as it is modified and updated. (24) 
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Recommended reporting guidelines for protocols and full reports 
IDEAL advocates that Stage 2a studies should report:  
• Patient inclusion and exclusion criteria, how many patients were assessed for 
treatment, which candidates were excluded, and the reasons for their exclusion.  
Patients considered for, but ultimately not offered the intervention may also be 
described, together with their outcomes. 
• Consecutive presentation of case-specific outcomes for all cases treated.  May 
involve use of statistical monitoring techniques eg, CUSUM (25)  
• When and why modifications to the technique or indications occurred, to reduce 
the risk of avoidable harm by preventing repetition of unsuccessful modifications. 
A graphic representation showing when technical modifications occurred during 
the series is useful.  
Ethical aspects  
Stage 2a studies are planned, and are therefore subject to appropriate institutional research 
ethics review.  Issues specific to Stage 2a are minimising harm during development of the new 
procedure, informed consent and transparent publication of outcomes. Consent should 
include information about Stage 1 outcomes, acknowledging that risks cannot be reliably 
predicted or quantified at this stage.  Collecting and reporting outcomes in accessible ways 
minimises avoidable harm to future patients and guides the fair and equitable uptake of 
innovation. In this and subsequent stages an independent oversight group to monitor 
outcomes during the study is highly desirable particularly for high risk procedures. (16) 
Identifying stage endpoints 
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By the end of this stage, the procedure and indications should be stable enough to permit 
multi-centre replication during Stage 2b.  The phase of intentional iterative change should be 
complete, although limited further modifications may still occur in Stage 2b.   
Areas for future work & research  
Further work is needed to guide development of protocols to plan Stage 2a studies, and to 
develop methods to evaluate when Stage 2a endpoints have been reached. (Appendix 1- link 
9) 
 
“Exploration” (Stage 2b) – Bridge to a pivotal trial 
Purpose and description 
In the ‘Exploration’ phase a greater experience of the new intervention is gained in a wider 
group of surgeons and patients to collect information which will determine whether and how 
to progress to a definitive comparison against current best treatment. The data should be 
used to promote consensus on the design and conduct of a future RCT, and to improve its 
feasibility by minimising potential barriers to delivery. (26, 27)   Chen at al (27) conducted a 
20-centre non-randomised prospective cohort study of treatments for uterine fibroids, in 
which patients chose to receive hysterectomy, myomectomy or HIFU therapy. The very large 
differences reported in complications and short term recovery ruled these out as primary 
outcomes for a future RCT, as equipoise appeared impossible.  Using QoL measures at 6 
months was also infeasible, as the very similar results found implied an enormous trial 
population requirement. There remained, however, an answerable question about 
recurrence after treatment. 
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Patients and operators: The patient group is less selective than for 2a studies, involving more 
patients in more centres; case numbers will commonly be over 100. More surgeons are 
learning and undertaking the new technique, and may disagree on inclusion criteria.  
Intervention and comparator: The intervention will now be relatively well defined, but minor 
differences in technique are still common and can be explored through pre-planned subgroup 
analyses. A comparator intervention may or may not exist. 
Outcomes: These include safety, a precise effect estimate of short term clinical outcome 
useful for trial size calculations, identification of possible subgroup outcome differences, 
assessment of surgical quality and learning curves, qualitative evaluation of trial feasibility 
and definition of core outcomes measures for the future trial. Validated core outcome 
measures should be used if available (Appendix 1- link 7). 
Appropriate study designs 
IDEAL Exploration studies are typically collaborative multi-centre prospective cohort studies 
and feasibility RCTs designed to enhance investigator consensus on key issues. The goal is to 
resolve the problems which most commonly prevent surgical RCTs: in doing so, however, 
Exploration studies may sometimes make it clear that an RCT is inappropriate or infeasible.  
In such cases Exploration studies may facilitate “next best” approaches such as propensity 
scoring of the observational data collected, or point to the need for a registry approach. We 
therefore recommend an early pre-planned consensus meeting to evaluate short term results 
and agree on whether an RCT can be done, and where feasible, to develop its design. 
Statistical analysis of learning curves may be useful. (28) 
Recommended reporting guidelines for protocols and full reports  
Guidance to assist design and reporting of Exploration Stage studies includes the recent 
CONSORT extension for pilot and feasibility RCTs (29) and the updated STROBE guideline for 
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observational studies (30). IDEAL’s development of a reporting checklist for this stage is 
underway.  
Ethical aspects  
Stage 2b studies require institutional research ethics review. Potential harms from the 
learning curve should be minimised by training and mentoring. Informed consent should be 
based upon information from Stage 2a. For reasons of justice and equity patient selection 
should reflect the population in which the innovation can be expected to be effective; and 
the data set should include outcomes of importance to patients.(16)  An independent study 
oversight group to monitor outcomes is recommended. 
Identifying Stage Endpoints   
By the end of Stage 2b, all the requirements needed to progress to a pivotal RCT should be 
complete.  These fall into two groups; 
a) Endpoints that demonstrate that the technique can be widely adopted by surgeons: 
1. Agreement on the definition of the intervention (and acceptable variants) for the 
purposes of an RCT; 
2. Agreement on quality standards for delivery of the intervention; and 
3. Assessment of learning curves to allow decisions on admission of clinicians into an RCT 
and how to evaluate their outcomes to avoid bias in a comparison versus standard 
treatment.  
b) Endpoints that demonstrate that progression to a formal randomised controlled trial is 
feasible: 
1. Confirmation of the appropriate target patient population. Disagreements on details 
of patient selection are a common cause of failure to achieve consensus for an RCT; 
2. Confirmation of the appropriate comparator treatment; 
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3. Confirmation of the appropriate primary endpoint for outcome assessment in the RCT. 
The DELTA guidance on specifying the target difference for a RCT is recommended 
(Table 2- link 10). 
4. Evidence of consensus amongst surgeons and patients that they are willing to accept 
randomisation between the proposed treatment options.  
We recommend the use of nested qualitative studies to explore the attitudes and values of 
participants. 
 
Areas for future research 
Successful Stage 2b Exploration studies require the collaboration of multiple researchers and 
institutions. These type of studies may therefore be especially suitable to cooperative groups 
such as the UK Surgical Trainee collaborative. (31) Methods for establishing that the 
intervention is sufficiently defined and stable for RCT evaluation need further work. Empirical 
evaluation of the impact of 2b studies on the probability of developing a successful RCT is 
needed. If large scale procedure registry systems or permanent audits exist, methods for 
nesting 2b studies within the system are needed.  
 
“Assessment” (Stage 3) – Pivotal study/RCT 
Purpose and description   
In the ‘Assessment’ Stage a pivotal comparative evaluation occurs, usually against current 
standard treatment. This should take place soon after the new procedure is stable, and prior 
to its extensive use, to avoid loss of equipoise among clinicians and patients.   
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Patients and operators: This will typically involve a substantial number of patients and 
operators at multiple centres. Clear patient and operator selection criteria should be based 
on data gathered in previous Stages. (26, 27) 
Intervention and comparator: The new intervention is compared with a clinically relevant 
comparator. Typically this will be “best usual care” but on occasions, a placebo or sham 
surgery control might be appropriate. (32) 
 
Outcomes: Outcomes reflecting the values of patients and operators should be identified 
during the Stage 2b collaborative study and consideration given to developing a new core 
outcome set (COS) if one does not already exist (33). IDEAL 2b studies provide opportunities 
to identify and pilot test the primary outcome for a definitive trial.  
Appropriate study designs 
Where feasible a multi-surgeon, multi-centre randomised trial (6, 34) should be performed. 
Variants, including cluster-randomised or expertise-based RCTs (35, 36) or stepped wedge 
designs may be appropriate. Where circumstances preclude randomisation, acceptable 
alternatives include controlled interrupted time series or observational designs using efficient 
post-hoc techniques (e.g. propensity scoring) to minimise known sources of bias. Nesting 
medical device based trials within national population/disease based registries is 
recommended to facilitate larger scale pragmatic trials (12) 
Recommended reporting guidelines for protocols and full reports  
Several robust guidelines for reporting surgical RCTs are recommended including the updated 
2010 CONSORT Statement (37), its extension for NPT (non-pharmacological treatments) (38) 
and a template for intervention description and replication (TIDieR Statement). (39)  
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The SPIRIT statement provides excellent guidance for writing protocols for RCTs. (40) These 
and other more specific reporting guidance for surgery can be found at the EQUATOR website 
(Appendix 1- link 4). 
Ethical aspects 
Stage 3 trials require institutional research ethics review and independent oversight. Relevant 
ethical issues concern the generation of valid data; fair inclusion and exclusion criteria; access 
and equity in research participation; use of outcomes relevant to patients; measures to 
minimise surgeon bias; efforts to minimise patient harm due to the learning curve; fair 
treatment of the data and prompt publication of all relevant results.  Placebo or sham surgery 
controls may be justifiable where they offer the best chance to resolve uncertainty, do not 
involve unacceptable risks to patients and are acceptable to key stakeholders (16). All RCTs 
should be registered on an appropriate international register, for example 
https://clinicaltrials.gov/ 
Identifying endpoints of stage 
The two main endpoints of Stage 3 are a) valid evidence on the intervention’s relative 
effectiveness; and b) identification of aspects which require long-term monitoring (typically 
late and rare outcomes).  
Areas for future work and research 
Many current initiatives will contribute to improvements in surgical trial design, conduct and 
reporting. These include Trial Forge (Appendix 1- link 11) to improve trial efficiency (41), and 
PRECIS-2, a tool to improve trial design (42). Research to establish better methods for early 
phase IDEAL studies is also being undertaken at the Bristol Centre for Surgical Research in the 
UK (Appendix 1- link 12).  
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“Long-term study” (Stage 4) – Identifying rare and later outcomes 
Purpose and description 
The IDEAL Framework proposes registries for data collection in Stage 4 (Long-term study). 
Their strength lies in recognising late or uncommon safety outcomes and identifying changes 
in the use of procedures - so called “indication creep”, and trends in outcomes which may 
reveal variations in the quality of surgery.    Registries allow evaluation of “real world” 
outcomes and, very importantly, can allow ongoing feedback to clinicians and manufacturer 
(43). This update of IDEAL introduces the recommendation for the use of registries at a much 
earlier stage in the framework. 
•     Registries for device surveillance and life cycle assessments. 
Registries or ‘registry like’ systems can detect long term or rare safety problems with devices 
such as the failures of metal-on-metal hip implants (44, 45), problems with vascular closure 
devices (46), and surgical meshes. (47, 48)  Comprehensive coverage requires commitment 
from users and sustainable partnership with stakeholders.  Registries should have 
independent supervision, use standard universally applicable definitions of outcomes and 
relevant confounders, and cover equivalent devices from all relevant manufacturers.  
However, manufacturers are often involved in registry funding, and are naturally wary of 
exposure of their data to competitors.  IDEAL promotes comprehensive, high quality 
registry/big data development whilst recognising the conflicts and the need to address 
stakeholder concerns (49). 
 
• Introducing registries at an early stage. 
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Whereas IDEAL originally envisaged registries as confined to Stage 4, registry-type data 
collection can usefully begin from IDEAL Stage 1. Device manufacturers typically develop 
competitor products more or less simultaneously, and evaluate them through exclusive 
arrangements with a relatively small pool of clinicians.  The evident scientific and public 
interest in pooling of these datasets is in tension with competition between manufacturers. 
Starting a registry at an early stage can allow data harmonization and pooling of resources 
and data if agreements can be reached (50 & Appendix 1- link 13). 
• Developing trials within registries 
IDEAL Stage 3 RCTs can be ‘nested’ within registries or cohort studies (51, 52 & Appendix 1 - 
link 14), potentially enhancing trial recruitment, but informed consent processes require 
careful consideration (see below). 
Patients & operators: The patient population is dictated by the stage at which the registry is 
introduced. Registries introduced at an early stage are mostly procedure or device driven with 
clinicians entering all patients treated with the innovation. Disease-driven registries, 
consisting of all known patients with a specific medical condition, are preferable scientifically 
but are not easy to implement and rarely sustainable.  A feasible compromise approach which 
facilitates nested trials and other secondary data usage is the “all comers” model which 
collects data on available treatments in a specific condition or area of practice (53). Advances 
in electronic records systems’ capacity to code accurately for both diagnosis and treatment 
will rapidly improve our ability to develop such registries in the future. 
Intervention & Comparator:  Registries may be procedure/device-driven or disease-driven. 
Which design is optimal depends on the objectives of the registry and should be clinician- and 
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patient driven. Registries can be utilised within specific trials where appropriate to increase 
their efficiency, for example the UK REBOA (Resuscitative Endovascular Balloon Occlusion of 
the Aorta) RCT will be using data collected via the UK trauma registry (Appendix 1 –link 15). 
Outcomes: Registries allow for analysis of long term outcomes that may not be captured 
within the lifetime of an RCT. Early stage registries may be particularly useful in allowing co-
operating innovators to pool learning on procedural modifications in order to arrive at the 
optimal technique more rapidly. 
Appropriate study designs 
Key design issues for registries centre on the dataset and on fostering engagement.  Datasets 
should be as small and cheap to collect as possible, whilst reliably capturing patient and 
device/procedure identity, diagnosis, and the key influences on outcome.  Standardised 
terminology should be used for all data items.  Careful design of contributor recognition, data 
entry systems and feedback methods should maximise incentives for and minimise barriers 
to full data submission.  
Recommended reporting guidelines for protocols and full reports 
Clear plans for analysis and reporting of data should be developed at the outset, specifying 
time intervals, numbers of patients registered, or pre-specified safety signals which will 
trigger analysis.  The form, authorship, and means of distribution of reports needs to be 
agreed in advance, giving all contributors appropriate recognition, notice of reports and 
access to the data. 
Ethical aspects  
In Stage 4, interventions are no longer within a research ethics framework, but part of routine 
clinical practice. However, as registry data is collected this raises issues about patient consent 
21 
 
 
for future use of data including the development of pragmatic nested RCTs. Integrated verbal 
consent can be an alternative to written consent in some contexts. (54) Issues of access and 
equity may arise in Stage 4 if the innovation is more expensive than alternatives, or 
concentrated in specialist centres. Conflicts of interest created by financial or reputational 
rewards and/or aggressive marketing may bias practice towards the innovation even for 
indications where there is little evidence. (16) 
Areas for further research 
Research is needed on the specific value of different features of registries, and on the factors 
which facilitate or prevent their introduction.  Further analysis of real world application of 
trials within registries is required to inform practical guidance and future IDEAL 
recommendations.   
Significant variation exists in the outcome measures used in international patient registries 
within the same clinical area, reducing their utility by making comparison, linkage, and 
aggregation of data more difficult. International collaborations are emerging to advance these 
issues (Appendix 1 links 16 and 17).   
LIMITATIONS 
The recommendations in this article arose from a relatively small selected group of experts. 
Different perspectives may have emerged with a wider range of participants. The use and 
uptake of IDEAL is continuously evolving, and this paper presents an update at a specific point 
in time. It will undoubtedly be refined further in the future. 
CONCLUSIONS 
The idea of an integrated stepwise evaluation pathway for complex interventions is generally 
accepted as desirable. The IDEAL approach meets this need in a logical and widely accepted 
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manner. However, IDEAL requires on-going review and updates. Experience in the planned 
use of the IDEAL Framework and Recommendations is currently limited. Empirical analysis of 
the outcomes and impact of using IDEAL will be an important driver for future incremental 
and evidence-based modifications.  
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